Trial Profile
An Exploratory Phase 2, 2-part, Randomized, Double blind, Placebo controlled Study With a Long term, Open label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2022
Price :
$35
*
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 10 Jun 2022 According to a Vertex media release, data from this study will be presented at 45th European Cystic Fibrosis Conference.
- 08 Nov 2021 Status changed from active, no longer recruiting to completed.
- 05 Nov 2021 This trial has been completed in Germany (Global end date: 7 Oct 2021).